AstraZeneca PLC AZN
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.03B | 10.45B | 10.39B | 10.23B | 9.40B |
| Total Depreciation and Amortization | 5.59B | 5.67B | 5.47B | 5.39B | 4.85B |
| Total Amortization of Deferred Charges | 236.00M | 236.00M | 236.00M | 236.00M | 200.00M |
| Total Other Non-Cash Items | -690.00M | -847.00M | -167.00M | -141.00M | 975.00M |
| Change in Net Operating Assets | -2.93B | -1.80B | -1.71B | -1.14B | -286.00M |
| Cash from Operations | 13.23B | 13.70B | 14.22B | 14.58B | 15.14B |
| Capital Expenditure | -3.02B | -3.03B | -2.93B | -2.81B | -2.48B |
| Sale of Property, Plant, and Equipment | 16.00M | 15.00M | 20.00M | 13.00M | 12.00M |
| Cash Acquisitions | -1.16B | -891.00M | -1.13B | -1.23B | -1.23B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.87B | -4.24B | -3.31B | -2.78B | -2.84B |
| Cash from Investing | -8.04B | -8.15B | -7.35B | -6.81B | -6.54B |
| Total Debt Issued | 5.41B | 2.95B | 3.60B | 379.00M | 819.00M |
| Total Debt Repaid | -4.85B | -4.84B | -2.41B | -2.40B | -412.00M |
| Issuance of Common Stock | 43.00M | 44.00M | 42.00M | 40.00M | 40.00M |
| Repurchase of Common Stock | -776.00M | -690.00M | -647.00M | -521.00M | -508.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.96B | -4.90B | -4.91B | -4.97B | -4.97B |
| Other Financing Activities | -346.00M | -369.00M | -371.00M | -195.00M | 76.00M |
| Cash from Financing | -5.35B | -7.68B | -4.57B | -7.54B | -4.93B |
| Foreign Exchange rate Adjustments | -12.00M | -17.00M | 3.00M | 46.00M | -19.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.00M | -2.15B | 2.31B | 269.00M | 3.65B |